|
|
||||||||



* Department of Immunology and Oncology, and Animal Facility, Centro Nacional de Biotecnología/Consejo Superior de Investigaciones Cientificas, Universidad Autónoma de Madrid, Cantoblanco, Madrid, Spain;
Department of Animal Medicine and Surgery, Veterinary School, Universidad Complutense de Madrid, Madrid, Spain;
Department of Genetics Biology and Biochemistry, University of Torino, Turin, Italy; and
Institute of Biochemistry, University of Fribourg, Fribourg, Switzerland
Class I PI3K catalyzes formation of 3-poly-phosphoinositides. The family is divided into IA isoforms, activated by Tyr kinases and the IB isoform (PI3K
), activated by G protein-coupled receptors. Mutations that affect PI3K are implicated in chronic inflammation, although the differential contribution of each isoform to pathology has not been elucidated. Enhanced activation of class IA-PI3K in T cells extends CD4+ memory cell survival, triggering an invasive lymphoproliferative disorder and systemic lupus. As both IA- and IB-PI3K isoforms regulate T cell activation, and activated pathogenic CD4+ memory cells are involved in triggering systemic lupus, we examined whether deletion of IB could reduce the pathological consequences of increased IA-PI3K activity. IB-PI3K
deficiency did not abolish invasion or lymphoproliferation, but reduced CD4+ memory cell survival, autoantibody production, glomerulonephritis, and systemic lupus. Deletion of the IB-PI3K
isoform thus decreased survival of pathogenic CD4+ memory cells, selectively inhibiting systemic lupus development. These results validate the PI3K
isoform as a target for systemic lupus erythematosus treatment.
This article has been cited by other articles:
![]() |
M. S. Thomas, J. S. Mitchell, C. C. DeNucci, A. L. Martin, and Y. Shimizu The p110{gamma} isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites J. Leukoc. Biol., September 1, 2008; 84(3): 814 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fougerat, S. Gayral, P. Gourdy, A. Schambourg, T. Ruckle, M. K. Schwarz, C. Rommel, E. Hirsch, J.-F. Arnal, J.-P. Salles, et al. Genetic and Pharmacological Targeting of Phosphoinositide 3-Kinase-{gamma} Reduces Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory Processes Circulation, March 11, 2008; 117(10): 1310 - 1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Martin, M. D. Schwartz, S. C. Jameson, and Y. Shimizu Selective Regulation of CD8 Effector T Cell Migration by the p110{gamma} Isoform of Phosphatidylinositol 3-Kinase J. Immunol., February 15, 2008; 180(4): 2081 - 2088. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Alcazar, M. Marques, A. Kumar, E. Hirsch, M. Wymann, A. C. Carrera, and D. F. Barber Phosphoinositide 3 kinase {gamma} participates in T cell receptor induced T cell activation J. Exp. Med., November 26, 2007; 204(12): 2977 - 2987. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |